Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.
about
Therapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisEstablishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide DrugsTherapeutic Potential of Tricyclo-DNA antisense oligonucleotidesIntegrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersDelivery is key: lessons learnt from developing splice-switching antisense therapiesFrom the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease miceAntisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.A snapshot of biologic drug development: Challenges and opportunities.The emerging role of long non-coding RNAs in cutaneous melanoma.A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs.Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse ModelAndrogen receptor in cancer-associated fibroblasts influences stemness in cancer cells.Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia.A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides.The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity.Natural antisense transcripts in diseases: From modes of action to targeted therapies.Circular RNAs: a new frontier for cancer diagnosis and therapy.Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.Advances in circular RNAs and their roles in breast Cancer
P2860
Q26782089-84AF7E09-999E-40D8-ACCD-CCEED5D5F86AQ28552808-453EBEB1-B8DA-481D-9559-4E6C7773A5ECQ28818017-11220626-6186-4BB6-A85C-CB44F7988EF6Q28821280-F825127A-8AD3-4047-BA61-971A031090CEQ33625875-D377BDE4-076C-4916-8827-A5EFF2BC2D9EQ33632091-1EDA91CB-E81E-4055-BC1D-95E3CE47CFC1Q36143261-CF858F15-8EBF-4E4C-AD3F-028AFF03D948Q36410111-E654099E-0AE7-47C1-A4EC-8E08561CDDD3Q38491805-EA903791-9645-4603-9DA7-DC71E609D19FQ38651271-1DA555C8-F0AC-4759-81DE-47A14C3E358AQ38949273-078FB303-0422-40C8-938C-01A9BDC30B77Q40140649-67DF6E02-B5A2-430D-94B3-F77F08BC3429Q41191017-120BBD23-F864-4AB4-B941-85417C2F1CD7Q41520323-7415041B-3293-48A7-A1B6-A4C1BB7EADA7Q46140457-F26E4C86-0A6D-4B57-87B9-A37B8028E9F8Q47109845-A229F06C-7124-43FC-B27C-AD1A1995F2CCQ47133501-AA0664FE-071D-4145-97EA-66A91821C7C0Q47159028-03AADBFB-FECC-4C13-8A35-C7A52704D47EQ48263612-EB2B40C4-5ADA-42CF-B6F8-FC1C35C4FEDBQ48569299-F42BAA04-C7D6-423A-B610-63F5E602E7C6Q49830924-DCE6A404-8049-45FB-AD8F-9C6DACA7C73DQ50006887-F1C4EFA0-5963-448D-87C1-51EFA11287DDQ50057827-6A2046D7-5DD3-4620-BEF6-816421320D0AQ52677688-969442EB-337E-4226-8C52-92ADB88CA9BDQ52738891-B55AC56E-D3AE-4DE6-9545-539CDAFACE0FQ53631590-1FEAD6D5-5A7B-45F0-8475-A9D51ADB8026Q57107429-84507F85-EC07-4AD1-9D5E-967547A320E3
P2860
Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@ast
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@en
type
label
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@ast
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@en
prefLabel
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@ast
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@en
P2860
P356
P1476
Antisense oligonucleotide ther ...... gic pathologist's perspective.
@en
P2093
Kendall S Frazier
P2860
P356
10.1177/0192623314551840
P407
P577
2014-11-09T00:00:00Z